Canine Serum amyloid A antibody and antigen (recombinant protein)

Diagnostic anti-Canine Serum amyloid A antibodies pairs and antigen for animal health (animal Dog/Canine amyloidosis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Companion Animal disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-CAN-Serum-amyloid-A-Ag01 Serum amyloid A $3090.00
GMP-CAN-Serum-amyloid-A-Ab01 Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb) $3090.00
GMP-CAN-Serum-amyloid-A-Ab02 Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb) $3090.00
GMP-CAN-Serum-amyloid-A-Ab03 Anti-Canine Serum amyloid A human monoclonal antibody (mAb) $3090.00
GMP-CAN-Serum-amyloid-A-Ab04 Anti-Canine Serum amyloid A human monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-CAN-Serum-amyloid-A-Ag01
Product Name Serum amyloid A
Target/Biomarker Serum amyloid A
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Canine Serum amyloid A antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Serum amyloid A level test of animal Dog/Canine with amyloidosis.
Tag His
Reconized/Reactive Specics Serum amyloid A
Product description Recombinant Canine Serum amyloid A protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-CAN-Serum-amyloid-A-Ab01,GMP-CAN-Serum-amyloid-A-Ab02
Target/Biomarker Serum amyloid A
Product Name Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb)
Expression platform Hybridoma
Isotypes Mouse IgG
Bioactivity validation Recombinant Canine Serum amyloid A antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Serum amyloid A antibodies in Serum amyloid A level test of animal Dog/Canine with amyloidosis.
Product description Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Serum amyloid A antibodies.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-CAN-Serum-amyloid-A-Ab03,GMP-CAN-Serum-amyloid-A-Ab04
Target/Biomarker Serum amyloid A
Product Name Anti-Canine Serum amyloid A human monoclonal antibody (mAb)
Expression platform CHO
Isotypes Human lgG1
Bioactivity validation Recombinant Canine Serum amyloid A antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Serum amyloid A antibodies in Serum amyloid A level test of animal Dog/Canine with amyloidosis.
Product description Anti-Canine Serum amyloid A mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Target/Biomarker Information


    SAA, or Serum Amyloid A, is a remarkable biomarker that occupies a central position in the immune response of dogs (canines) to inflammatory challenges. This protein is primarily synthesized by hepatocytes in the liver and is swiftly released into the bloodstream in response to various inflammatory signals. Its role as an acute-phase protein is fundamental to the canine immune system's ability to detect and combat inflammation, infection, and tissue damage.

    Structurally, SAA comprises two primary isoforms in dogs, SAA1 and SAA2, both of which can be elevated during inflammatory conditions. These isoforms play a pivotal role in modulating the host's immune response to pathogens and injuries. SAA acts as a chemoattractant for immune cells, facilitating their migration to the site of infection or inflammation. Additionally, SAA can influence other immune responses, including the production of cytokines and other inflammatory mediators.

    In dogs, SAA serves as a sensitive and early marker of systemic inflammation. When exposed to inflammatory stimuli, such as infections, tissue damage, or other inflammatory conditions, the liver rapidly increases the synthesis of SAA. Elevated levels of SAA in the bloodstream can be detected within hours of the initial trigger, making it a valuable diagnostic tool for veterinarians.

    The measurement of SAA in dogs transcends routine biomarker assessment; it represents a cornerstone of canine healthcare and scientific inquiry. The multifaceted significance of SAA encompasses various aspects of veterinary medicine and research.

    Firstly, SAA is a sentinel of inflammation in dogs. Its rapid and robust response to inflammatory stimuli positions it as an indispensable diagnostic tool for veterinarians. Elevated SAA levels can indicate the presence of infectious diseases, inflammatory conditions, or tissue damage. The ability to detect such conditions early is instrumental in implementing timely interventions, initiating appropriate treatment strategies, and mitigating disease progression.

    Secondly, SAA monitoring plays a pivotal role in disease management and treatment evaluation. By quantifying fluctuations in SAA levels over time, veterinarians can assess the effectiveness of therapeutic interventions. This dynamic monitoring enables timely adjustments to treatment plans, enhancing the likelihood of favorable outcomes for dogs. Additionally, SAA measurements provide valuable insights into the severity of inflammation and the systemic impact of various canine diseases, aiding in disease stratification and treatment decision-making.

    Beyond its diagnostic and therapeutic applications, SAA serves as a bridge between clinical veterinary practice and scientific research in dogs. Ongoing investigations into SAA dynamics in different disease contexts expand our understanding of canine immunology and the intricate interplay between inflammation, infection, and tissue repair. These studies not only contribute to the advancement of canine healthcare but also pave the way for the development of innovative diagnostic and therapeutic strategies.

    In conclusion, SAA in dogs is more than a biomarker; it is a sentinel of inflammation, a linchpin in disease management, and a conduit for scientific exploration. The measurement of SAA in canines embodies the fusion of clinical veterinary expertise and cutting-edge scientific inquiry, ultimately promoting the health and well-being of canine populations worldwide.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.